心房颤动合并中风患者的直接口服抗凝剂失败:回顾性入院分析和新的分类系统

IF 0.9 Q4 CLINICAL NEUROLOGY Neurohospitalist Pub Date : 2023-07-01 Epub Date: 2023-05-12 DOI:10.1177/19418744231161390
David Z Rose, Jane Y Chang, Xiyan Yi, Kevin Kip, Yuanyuan Lu, N Corbin Hilker, Abdelrahman Beltagy
{"title":"心房颤动合并中风患者的直接口服抗凝剂失败:回顾性入院分析和新的分类系统","authors":"David Z Rose, Jane Y Chang, Xiyan Yi, Kevin Kip, Yuanyuan Lu, N Corbin Hilker, Abdelrahman Beltagy","doi":"10.1177/19418744231161390","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breakthrough acute ischemic stroke (AIS) in patients with known, nonvalvular Atrial Fibrillation (AF), on Direct Oral Anticoagulants (DOAC), is an ongoing clinical conundrum. Switching anticoagulants was shown to be ineffective in preventing recurrent AIS. Systematic, patient-level chart review of so-called \"DOAC failures\" may offer insight into this phenomenon.</p><p><strong>Methods: </strong>We conducted an IRB-approved, 6-year, retrospective study of AIS admissions, already prescribed DOAC for known AF. We sought plausible, alternative reasons for the AIS using a novel classification schema, CLAMP: C for Compliance concerns, L for Lacunes (small-vessel disease), A for Arteriopathy (atherosclerosis, web, or vasculitis), M for Malignancy, and P for Patent Foramen Ovale (PFO). These categories were labeled as DOAC \"Pseudo-failures.\" Conversely, absence of CLAMP variables were labeled as DOAC \"Crypto-failures\" conceivably from AF itself (\"atriopathy\") or pharmacokinetic/pharmacogenomic dysfunction (ie, altered DOAC absorption, clearance, metabolism, or genetic polymorphisms). Forward logistic regression analysis was performed on prespecified DOAC subgroups.</p><p><strong>Results: </strong>Of 4890 AIS admissions, 606 had AF, and 87 were previously prescribed DOAC (14.4% overall DOAC failure rate, 2.4% annualized over 6 years). Pseudo-failures comprised 77%: Compliance concerns (48.9%), Lacunes (5.7%), Arteriopathy (17.0%), Malignancy (26.1%), and PFO (2.3%). Crypto-failures comprised 23%, had lower CHADSVASc scores (AOR = .65, P = .013), and occurred more with rivaroxaban (41%) than apixaban (16%) or dabigatran (5.6%).</p><p><strong>Conclusion: </strong>In AIS patients with known AF, DOAC Pseudo-failures, with identified alternate etiologies, are 3 times more likely than DOAC Crypto-failures. The CLAMP schema represents a novel approach to diagnostic classification and therapeutic adjustments in patients already prescribed DOAC for AF.</p>","PeriodicalId":46355,"journal":{"name":"Neurohospitalist","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334065/pdf/","citationCount":"0","resultStr":"{\"title\":\"Direct Oral Anticoagulant Failures in Atrial Fibrillation With Stroke: Retrospective Admission Analysis and Novel Classification System.\",\"authors\":\"David Z Rose, Jane Y Chang, Xiyan Yi, Kevin Kip, Yuanyuan Lu, N Corbin Hilker, Abdelrahman Beltagy\",\"doi\":\"10.1177/19418744231161390\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Breakthrough acute ischemic stroke (AIS) in patients with known, nonvalvular Atrial Fibrillation (AF), on Direct Oral Anticoagulants (DOAC), is an ongoing clinical conundrum. Switching anticoagulants was shown to be ineffective in preventing recurrent AIS. Systematic, patient-level chart review of so-called \\\"DOAC failures\\\" may offer insight into this phenomenon.</p><p><strong>Methods: </strong>We conducted an IRB-approved, 6-year, retrospective study of AIS admissions, already prescribed DOAC for known AF. We sought plausible, alternative reasons for the AIS using a novel classification schema, CLAMP: C for Compliance concerns, L for Lacunes (small-vessel disease), A for Arteriopathy (atherosclerosis, web, or vasculitis), M for Malignancy, and P for Patent Foramen Ovale (PFO). These categories were labeled as DOAC \\\"Pseudo-failures.\\\" Conversely, absence of CLAMP variables were labeled as DOAC \\\"Crypto-failures\\\" conceivably from AF itself (\\\"atriopathy\\\") or pharmacokinetic/pharmacogenomic dysfunction (ie, altered DOAC absorption, clearance, metabolism, or genetic polymorphisms). Forward logistic regression analysis was performed on prespecified DOAC subgroups.</p><p><strong>Results: </strong>Of 4890 AIS admissions, 606 had AF, and 87 were previously prescribed DOAC (14.4% overall DOAC failure rate, 2.4% annualized over 6 years). Pseudo-failures comprised 77%: Compliance concerns (48.9%), Lacunes (5.7%), Arteriopathy (17.0%), Malignancy (26.1%), and PFO (2.3%). Crypto-failures comprised 23%, had lower CHADSVASc scores (AOR = .65, P = .013), and occurred more with rivaroxaban (41%) than apixaban (16%) or dabigatran (5.6%).</p><p><strong>Conclusion: </strong>In AIS patients with known AF, DOAC Pseudo-failures, with identified alternate etiologies, are 3 times more likely than DOAC Crypto-failures. The CLAMP schema represents a novel approach to diagnostic classification and therapeutic adjustments in patients already prescribed DOAC for AF.</p>\",\"PeriodicalId\":46355,\"journal\":{\"name\":\"Neurohospitalist\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334065/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurohospitalist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/19418744231161390\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/5/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurohospitalist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19418744231161390","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:服用直接口服抗凝药(DOAC)的已知非瓣膜性心房颤动(AF)患者发生突破性急性缺血性中风(AIS)是一个持续存在的临床难题。事实证明,更换抗凝药物并不能有效预防复发性 AIS。对所谓的 "DOAC 失败病例 "进行系统的、患者级别的病历审查可能有助于深入了解这一现象:我们对已开 DOAC 治疗已知房颤的入院 AIS 患者进行了一项经 IRB 批准、为期 6 年的回顾性研究。我们使用新颖的分类模式 CLAMP 寻找 AIS 的其他合理原因:C代表合规性问题,L代表小血管疾病,A代表动脉病变(动脉粥样硬化、网状血管或脉管炎),M代表恶性肿瘤,P代表卵圆孔孔(PFO)。这些类别被称为 DOAC "伪失败"。相反,不存在 CLAMP 变量的患者被称为 DOAC "隐性失效",可能是房颤本身("房颤病")或药代动力学/药物基因组学功能障碍(即 DOAC 吸收、清除、代谢或基因多态性改变)引起的。对预先指定的 DOAC 亚组进行了前向逻辑回归分析:在 4890 例入院的 AIS 患者中,606 例患有房颤,87 例之前服用过 DOAC(DOAC 总失败率为 14.4%,6 年的年化失败率为 2.4%)。假性失败占 77%:依从性问题(48.9%)、Lacunes(5.7%)、动脉病变(17.0%)、恶性肿瘤(26.1%)和 PFO(2.3%)。隐匿性心律失常占23%,CHADSVASc评分较低(AOR = .65,P = .013),利伐沙班(41%)的发生率高于阿哌沙班(16%)或达比加群(5.6%):结论:在已知心房颤动的 AIS 患者中,DOAC 伪失效(已确定替代病因)的可能性是 DOAC 隐性失效的 3 倍。CLAMP 模式代表了一种新的诊断分类方法,可对已服用 DOAC 治疗房颤的患者进行治疗调整。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Direct Oral Anticoagulant Failures in Atrial Fibrillation With Stroke: Retrospective Admission Analysis and Novel Classification System.

Introduction: Breakthrough acute ischemic stroke (AIS) in patients with known, nonvalvular Atrial Fibrillation (AF), on Direct Oral Anticoagulants (DOAC), is an ongoing clinical conundrum. Switching anticoagulants was shown to be ineffective in preventing recurrent AIS. Systematic, patient-level chart review of so-called "DOAC failures" may offer insight into this phenomenon.

Methods: We conducted an IRB-approved, 6-year, retrospective study of AIS admissions, already prescribed DOAC for known AF. We sought plausible, alternative reasons for the AIS using a novel classification schema, CLAMP: C for Compliance concerns, L for Lacunes (small-vessel disease), A for Arteriopathy (atherosclerosis, web, or vasculitis), M for Malignancy, and P for Patent Foramen Ovale (PFO). These categories were labeled as DOAC "Pseudo-failures." Conversely, absence of CLAMP variables were labeled as DOAC "Crypto-failures" conceivably from AF itself ("atriopathy") or pharmacokinetic/pharmacogenomic dysfunction (ie, altered DOAC absorption, clearance, metabolism, or genetic polymorphisms). Forward logistic regression analysis was performed on prespecified DOAC subgroups.

Results: Of 4890 AIS admissions, 606 had AF, and 87 were previously prescribed DOAC (14.4% overall DOAC failure rate, 2.4% annualized over 6 years). Pseudo-failures comprised 77%: Compliance concerns (48.9%), Lacunes (5.7%), Arteriopathy (17.0%), Malignancy (26.1%), and PFO (2.3%). Crypto-failures comprised 23%, had lower CHADSVASc scores (AOR = .65, P = .013), and occurred more with rivaroxaban (41%) than apixaban (16%) or dabigatran (5.6%).

Conclusion: In AIS patients with known AF, DOAC Pseudo-failures, with identified alternate etiologies, are 3 times more likely than DOAC Crypto-failures. The CLAMP schema represents a novel approach to diagnostic classification and therapeutic adjustments in patients already prescribed DOAC for AF.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neurohospitalist
Neurohospitalist CLINICAL NEUROLOGY-
CiteScore
1.60
自引率
0.00%
发文量
108
期刊最新文献
"Recurrent Pleomorphic Xanthoastrocytoma Presenting with Diffuse Leptomeningeal Spread". Clinical Problem-Solving: A 19-Year-Old Woman With Progressive Neurological Decline and Multiple Intracranial Lesions. Comparison of Telemedicine-Administered Thrombolytic Therapy for Acute Ischemic Stroke by Neurology Subspecialty: A Cross-Sectional Study. Complete Third Nerve Palsy: A Rare Occurrence in Fulminant IIH Case Report. Concurrent Miller Fisher Syndrome and Immune Thrombocytopenic Purpura: A Case Report and Review of the Literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1